Obesity and the lung: 5 · Obesity and COPD

F M E Franssen,¹ D E O'Donnell,² G H Goossens,³ E E Blaak,³ A M W J Schols¹

¹ Department of Respiratory Medicine, University Hospital Maastricht, Maastricht, The Netherlands; ² Division of Respiratory and Critical Care Medicine, Department of Medicine, Queens University, Kingston, Ontario, Canada; ³ Department of Human Biology, Nutrition and Toxicology Research Institute (NUTRIM), Maastricht University, Maastricht, The Netherlands

Correspondence to: Dr A M W J Schols, NUTRIM School for Nutrition, Toxicology and Metabolism, Department of Respiratory Medicine, University Hospital Maastricht, P O Box 5800, 6202 AZ Maastricht, The Netherlands; a.schols@pul.unimaas.nl

Received 15 February 2008
Accepted 30 April 2008

ABSTRACT

Chronic obstructive pulmonary disease (COPD) and obesity are common and disabling chronic health conditions with increasing prevalence worldwide. A relationship between COPD and obesity is increasingly recognised, although the nature of this association remains unknown. This review focuses on the epidemiology of obesity in COPD and the impact of excessive fat mass on lung function, exercise capacity and prognosis. The evidence for altered adipose tissue functions in obesity—including reduced lipid storage capacity, altered expression and secretion of inflammatory factors, adipose tissue hypoxia and macrophage infiltration in adipose tissue—is also reviewed. The interrelationship between these factors and their contribution to the development of insulin resistance in obesity is considered. It is proposed that, in patients with COPD, reduced oxidative capacity and systemic hypoxia may amplify these disturbances, not only in obese patients but also in subjects with hidden loss of fat-free mass. The potential interaction between abnormal adipose tissue function, systemic inflammation and COPD may provide more insight into the pathogenesis and reversibility of systemic pathology in this disease.

Chronic obstructive pulmonary disease (COPD) and obesity are major causes of morbidity and mortality worldwide and, according to current estimates, the global burden of these conditions will increase further. While spirometry is used for diagnosis and gradation of COPD severity according to the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines,¹ classification of overweight and obesity is based on body mass index (BMI) as defined by the World Health Organization (WHO).²

According to the Burden of Obstructive Lung Disease (BOLD) Initiative,³ the estimated international prevalence of stage II or higher COPD is currently 10.1% in individuals aged 40 years and older. COPD was the fifth leading cause of mortality around the world in 2001 and will be the third most frequent cause of death by the year 2020.⁴ The prevalence of obesity, defined as BMI ≥ 30 kg/m²,² has multiplied during the last decades and varies from 10–20% in most European countries to $>32\%$ in the USA.² According to the most recent global WHO projections, 400 million adults were obese in 2005 and it is estimated that this number will exceed 700 million by the year 2015.⁵ Obesity plays a major role in the development of the metabolic syndrome and has been identified as an important risk factor for chronic diseases such as type 2 diabetes mellitus and cardiovascular disease. It is linked to respiratory diseases such as obstructive sleep apnoea syndrome and obesity hypoventilation syndrome,⁶ and accumulating

evidence suggests an association between obesity and asthma.⁷ A potential link between obesity and COPD is also increasingly recognised,⁸ although very little is known about the mechanisms underlying this association. The risk of developing obesity is increased in patients with COPD as a result of a reduced level of physical activities in daily life in these patients compared with healthy age-matched controls.⁹ In addition, in theory, patients with COPD who receive repeated courses of systemic glucocorticosteroids are at increased risk of truncal obesity as a result of glucocorticoid-mediated redistribution of stored energy and the stimulatory effect on intake.¹⁰

PREVALENCE OF OBESITY IN COPD

Steuten *et al*¹¹ studied the prevalence of obesity in a large primary care population of patients with COPD in the Netherlands. The overall prevalence of obesity in this population was 18%, with the highest prevalence in GOLD stages 1 and 2 (16–24%) and the lowest in GOLD stage 4 (6%). For comparison, the current prevalence of obesity in the general population in the Netherlands is 10% in adult men and 12% in adult women.¹² A much higher prevalence of obesity was reported by Eisner *et al*¹³ in an adult multi-ethnic cohort of patients with early stage COPD in Northern California, USA; 54% of the patients with COPD had a BMI ≥ 30 kg/m², which is considerably more than the 20–24% of obese individuals in the same US state reported by the Centers for Disease Control and Prevention using annual data from the Behavioural Risk Factor Surveillance System (www.cdc.gov/BRFSS/). Thus, available data suggest that obesity is more prevalent in patients with COPD than in the general population, depending on the severity of chronic airflow limitation. Indeed, a study in moderately severe patients participating in cardio-pulmonary rehabilitation showed that abdominal obesity measured by waist circumference was almost twice as common in patients with COPD as in age- and sex-matched controls.¹⁴ In addition, the occurrence of obesity might differ between various clinical phenotypes of COPD. The classical distinction of “pink puffers” and “blue bloaters” was based on anthropometric characteristics of patients with emphysema and chronic bronchitis, respectively. By definition, “pink puffers” were thin in appearance with a frequent history of weight loss while “blue bloaters” showed no marked weight loss and tended to be overweight.¹⁵ In fact, a significantly increased prevalence of (pre)obesity (BMI ≥ 28 kg/m²) was reported in patients with chronic bronchitis (25%) compared with controls (16%) in the Tucson prospective cohort study,¹⁶ while underweight was more prevalent in patients with emphysema.

There are no published studies on the prevalence of COPD in obesity. However, data from the 4th examination of The Copenhagen City Heart Study suggest that the prevalence of COPD in obese individuals is significantly lower than in the rest of the population (11.2% vs 18.6%) owing to a lower occurrence of mild and moderate disease (personal communication, Jørgen Vestbo, Copenhagen, Denmark).

In addition to obesity characterised by an absolute abundance of fat mass in patients with COPD, it is well recognised that alterations in body composition also commonly occur in normal weight patients with COPD. Selective wasting of fat-free mass (FFM; ie, muscle mass) occurs in 10–15% of normal weight patients with COPD,^{17 18} resulting in a relative or absolute increase in fat mass.¹⁹ This situation shows a resemblance to the involuntary loss of muscle mass with advanced age defined as sarcopenia.²⁰

EFFECT OF OBESITY ON RESPIRATORY FUNCTION AND EXERCISE PERFORMANCE

In any given individual the effects of obesity on respiratory function depend on the mass and anatomical distribution of the excessive adipose tissue on the thorax and abdomen.^{21 22} The nature of the physiological impairment induced by obesity will vary with its extent and will ultimately reflect integrated abnormalities of ventilatory mechanics/muscle function, pulmonary gas exchange, ventilatory control and cardiac performance.^{21–35} These respiratory derangements are consistently accentuated on adopting the supine posture. Common physiological abnormalities associated with eucapnic obesity (excluding obesity hypoventilation syndrome) are listed in box 1. Restrictive mechanics are manifest by reduced expiratory reserve volume and functional residual capacity. Residual volume and total lung capacity are preserved except in extreme obesity. The forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) ratio is preserved but tests of small airway function may be abnormal.^{21–35} Lung carbon monoxide transfer factor (TLCO) is in the normal range or increased and gas exchange is compromised in severe obesity, particularly in the supine posture. Normative predictive equations for spirometric measurements, plethysmographic lung volumes and TLCO are generally not corrected for weight. This has implications for the clinical interpretation of pulmonary function tests in the overweight and obese who comprise an increasing proportion of those tested.

Exercise performance

Peak oxygen uptake ($\dot{V}O_2$) corrected for weight is surprisingly preserved in obesity, at least during weight-supported cycle

exercise.^{27 36–38} When comparing oxygen uptake measurements during exercise in obese individuals with predictive normal values, underestimation in the former can be avoided by expressing $\dot{V}O_2$ as a percentage of ideal body weight. Obese individuals have a higher metabolic demand at any given power output as a result of the high oxygen cost of lifting heavy limbs.^{27 36–38} Pulmonary gas exchange is rarely critically compromised in obesity and arterial oxygen saturation may even improve during exercise, reflecting an improvement in ventilation/perfusion relationships.^{27 36–38} Patients with obesity may have expiratory flow limitation at rest which, when compounded by high ventilatory requirements, leads to significant air trapping and dynamic increase in end-expiratory lung volume during exercise (fig 1).^{27 37 38} Given the increase in ventilatory demand (secondary to increased metabolic loading) and the excessive intrinsic mechanical loading of the inspiratory muscles in obesity, the muscular effort required to support a given ventilation is increased at any given power output compared with individuals of normal weight.^{38–40} Not surprisingly, the work and oxygen cost of breathing is also increased at rest and during exercise.^{36 39 41 42} Exertional dyspnoea intensity is uniformly increased for any given power output and rises sharply as ventilation (and therefore contractile muscle effort) approach maximal capacity.²⁷ In some patients, exercise performance is further compromised by attendant skeletal muscle deconditioning, peripheral muscle dysfunction and cardiac impairment (eg, eccentric left ventricular hypertrophy of obesity).^{43 44}

Combined deleterious effects of obesity and COPD

The physiological derangements that occur at rest and during exercise in obesity and in COPD are well understood when each is considered in isolation. However, no mechanistic studies have explored the pathophysiological interactions that occur when both conditions coexist in the same individual, as is increasingly the case. Given the vast pathophysiological heterogeneity of COPD, the concomitant effects of aging and sex on physical performance, and the existence in many of serious comorbidities in conjunction with obesity, the mechanisms of exercise intolerance in obese patients with COPD are necessarily complex. Clinical experience indicates that the combined restrictive/obstructive deficits evident in obese patients with COPD culminate in worsening symptomatology and activity limitation.^{8 45 46} Obesity would be expected to amplify the abnormalities of dynamic ventilatory mechanics and ventilatory demand that characterise COPD. Thus, ventilatory requirements are predictably higher in obese patients with COPD compared with those of normal weight as a result of the increase in chemostimulation that arises from the combination of increased metabolic loading, high fixed physiological dead space and possibly earlier metabolic acidosis due to impairment in oxygen uptake from deconditioning or cardiac dysfunction. The increased recoil of the chest wall and lung in patients with central obesity may increase expiratory flow rates at a given operating lung volume compared with non-obese patients with COPD. However, the relatively reduced absolute end-expiratory lung volume in obese patients with COPD may worsen expiratory flow limitation and air trapping during exercise (fig 1), particularly in the setting of the relatively increased ventilatory requirement.^{47 48} The net effect of these abnormalities is an earlier mechanical limitation of ventilation with greater dyspnoea and exercise curtailment in the obese patient with COPD. The accompanying rapid shallow breathing pattern (at a relatively low power output and ventilation) may compromise dynamic inspiratory muscle function and

Box 1 Respiratory function in eucapnic obesity

- ▶ Decreased chest wall and lung compliance
- ▶ Small airway dysfunction and expiratory flow limitation
- ▶ Preservation of the forced expiratory volume in 1s/forced vital capacity ratio
- ▶ Variable reduction of (or preserved) ventilatory muscle strength and endurance
- ▶ Increased work and oxygen cost of breathing
- ▶ Normal or increased carbon monoxide transfer factor
- ▶ Abnormal ventilation/perfusion relations and arterial oxygen desaturation
- ▶ Normal or increased central respiratory drive

Figure 1 Maximal and tidal flow-volume loops for a series of age-matched women: a lean woman with normal lung function, an obese woman with normal lung function, a lean woman with COPD (forced expiratory volume in 1 s (FEV₁) 46% predicted) and an obese woman with COPD (FEV₁ 45% predicted). Inner tidal loops are shown at rest (solid inner loops) and at ventilations of ~32 l/min (dotted loops), the latter corresponding to the symptom-limited peak of exercise for both women with COPD. While the end-expiratory lung volume was decreased during exercise in the healthy lean woman, the other women experienced dynamic pulmonary hyperinflation (leftward arrows). Additional flow and volume constraints on tidal volume expansion in the women with COPD limited the peak ventilation that could be attained during exercise. In women with COPD a critically reduced inspiratory reserve volume (IRV) limited any further increase in tidal volume during exercise and resulted in severe exertional dyspnoea. Ratings of dyspnoea intensity using the modified 10-point Borg scale are shown at comparable ventilations during exercise. BMI, body mass index.

deleteriously affect alveolar ventilation.^{47–49} In obese patients with COPD the increased contractile muscle effort required to sustain ventilation during exercise in the face of serious mechanical constraints on tidal volume expansion would be expected to cause significant neuromechanical uncoupling of the respiratory system and lead to incapacitating dyspnoea earlier in exercise than in non-obese patients with COPD.

Effects of body composition on exercise performance in obese COPD

In addition to ventilatory limitations, alterations in body composition contribute to exercise intolerance in patients with COPD. It is well recognised that loss of FFM contributes to muscle weakness⁵⁰ and reduced exercise capacity⁵¹ in patients with moderate to severe COPD. Available data in these patients suggest that the contribution of alterations in fat mass to exercise intolerance is limited compared with the impact of muscle wasting. The degree of physical impairment, assessed by the 12 minute walking test, was greater in normal weight patients with depleted FFM and relatively enhanced fat mass than in underweight patients with preserved FFM.¹⁷ Less is known about effects of obesity or relatively increased fat mass on physical performance in patients with less severe COPD. In patients with early stage COPD, obesity, decreased lean-to-fat mass ratio and increased sagittal abdominal diameter were associated with functional limitation on the six minute walk test.¹³ The accumulation of fat mass and not the loss of lean mass had a particularly negative impact on performance. This observation is not unique for patients with early stage COPD.

In a cohort of elderly individuals from the general population, high body fatness was associated with increased risk of self-reported mobility-related disability, while low FFM was not predictive of disability.⁵² In another community-based cohort study of older individuals, higher fat mass was related to an increased risk of functional limitation assessed by walking speed.⁵³ Although absolute lean mass was not related to physical performance, a higher ratio of lean mass to fat mass was predictive of walking speed. Thus, it seems that both absolute and relative accumulation of fat mass contribute to functional limitation in the elderly and early in the course of COPD, while the influence of muscle wasting on physical performance becomes apparent in patients with more severe COPD when FFM falls to very low levels.^{17 54}

THE OBESITY PARADOX IN COPD

The prognostic value of nutritional status is well established in patients with COPD. Low BMI is associated with increased all-cause and COPD-related mortality, unrelated to disease severity.⁵⁵ Recent studies indicate that the FFM index is an even more important determinant of prognosis in moderate to severe COPD than BMI.^{18 54} Fat mass index was not predictive for prognosis in patients with moderate to severe COPD.⁵⁴ Remarkably, the relative risk for mortality seems decreased in overweight and obese patients with COPD in GOLD stage 3–4, while it is increased in those with GOLD stage 1–2 disease with (pre)obesity.⁵⁵ A possibly protective role for obesity in COPD was also observed in early studies on the association between body weight and mortality,⁵⁶ in the epidemiological

Copenhagen City Heart Study¹⁸ and in a population of patients with severe COPD treated with long-term oxygen therapy.⁵⁷ This possible association between (pre)obesity and improved outcome in COPD contrasts with epidemiological data from the general population where obesity is associated with a largely decreased life expectancy, independent of smoking status.⁵⁸ This phenomenon is referred to as a “reverse epidemiology of obesity” or the “obesity paradox” and was identified in several other chronic disease states such as end-stage chronic kidney disease, chronic heart failure and rheumatoid arthritis.⁵⁹ The pathophysiological mechanisms of the obesity paradox are yet to be unravelled. In obese men with COPD the annual decline in FEV₁ was significantly lower than in men of normal BMI range while this effect was not seen in women.⁶⁰ This suggests a gender-specific protective role for obesity in the progression of chronic airflow limitation. Furthermore, it is not yet clear whether excessive fat mass or muscle mass contributes to the survival advantage in chronic wasting diseases.⁵⁹

In apparent contradiction to the possible existence of an obesity paradox in COPD, it is well recognised that the risk of cardiovascular mortality is increased in patients with chronic airflow limitation, independent of BMI.⁶¹ Epidemiological studies indicate that low FEV₁ is a risk factor for coronary heart disease in subjects without pulmonary disease.⁶² Besides the presence of chronic airflow obstruction, low-grade systemic inflammation is one of the mechanisms that may be responsible for the increased rate of cardiovascular complications in COPD.⁶³ The role for smoking-related systemic inflammation is evident in the pathogenesis of COPD and led to the proposal of the term “chronic systemic inflammatory syndrome” complementary to the diagnosis of COPD.⁶⁴ Insulin resistance may also contribute to the increased cardiovascular mortality in patients with COPD. It plays an important role in the pathogenesis of type 2 diabetes mellitus and it clusters with a variety of risk factors for cardiovascular disease, such as abdominal obesity, dyslipidaemia and hypertension in the metabolic syndrome.⁶⁵ In a recent meta-analysis of longitudinal studies, the presence of the metabolic syndrome was strongly associated with cardiovascular morbidity and mortality.⁶⁶ Indeed, some studies suggest the presence of insulin resistance in COPD,⁶⁷ especially in normal weight to obese patients^{68–69} and those who are hypoxaemic.⁶⁹

Based on the evidence outlined above, it can be hypothesised that obesity exerts divergent effects in subgroups of COPD with different severity of disease. Obesity may protect against mortality in patients with advanced COPD in whom loss of FFM is a particularly important short-term risk factor for death. By contrast, in earlier stage COPD the harmful long-term effects of obesity-related conditions such as low-grade systemic inflammation and insulin resistance may result in increased cardiovascular and all-cause mortality.

The implications of obesity for the pharmacological and extrapulmonary management of patients with COPD are still unknown. In recent years, new insights into the functioning of adipose tissue in obesity have evolved. These are reviewed in the next section and may help to further unravel the clinical significance and pathophysiology of obesity in COPD.

ADIPOSE TISSUE DYSFUNCTION IN OBESITY AND THE INFLUENCE OF HYPOXIA

The association between abdominal obesity, insulin resistance and cardiovascular disease is well recognised,⁷⁰ but the underlying mechanisms are not yet fully understood. Adiposity is associated with insulin resistance even over relatively normal

ranges of body fatness. There is strong evidence that altered adipose tissue function plays a crucial role in the pathogenesis of obesity-related insulin resistance and type 2 diabetes, as has recently been reviewed.⁷¹

Lipid storage capacity of adipose tissue in obesity

Adipose tissue is the main lipid storage depot in the body and is of crucial importance in buffering the daily influx of dietary fat entering the circulation. One characteristic of adipose tissue in obesity is the enlargement of adipocytes which may represent impaired adipocyte differentiation. The hypertrophic adipocytes of obese subjects are overloaded with stored triacylglycerol and it is likely that the buffering capacity for further lipid storage in these adipocytes is decreased, especially in the postprandial state.⁷² Non-adipose tissues are therefore exposed to an excessive influx of lipids which could lead to ectopic fat deposition when the oxidative capacity is insufficient. It is well established that accumulation of lipids in skeletal muscle,⁷³ pancreatic islets⁷⁴ and the liver⁷⁵ play an important role in the development of insulin resistance and/or impaired insulin secretion in obese individuals. Another possible explanation for the observation that adipocyte hypertrophy is associated with insulin resistance and the development of type 2 diabetes relates to the endocrine function of adipose tissue.

Adipose tissue as a source of inflammation in obesity

Adipocytes express and secrete a variety of adipokines—including cytokines, growth factors, adiponectin, resistin, adipisin, leptin, acylation stimulating protein (ASP), plasminogen activator inhibitor-1 (PAI-1), lipoprotein lipase (LPL) and components of the renin-angiotensin system⁷⁶—which may exert local and systemic effects. Chronic low-grade inflammation is a hallmark of obesity, insulin resistance and type 2 diabetes.^{77–78} Importantly, inflammatory pathways play a prominent role in the mechanisms underlying insulin resistance and type 2 diabetes in cultured cells and animal models,^{79–81} and this may also be the case in humans.

The inflammatory response that is often present in obesity appears to be triggered and to reside predominantly in the enlarged adipose tissue.^{82–85} The expression and/or secretion of inflammatory molecules, including tumour necrosis factor α (TNF α),^{84–86–87} interleukin (IL)6,^{86–88} PAI-1⁸⁹ and leptin,^{87–90} are increased in the adipose tissue of obese insulin-resistant individuals. In contrast, the expression of the insulin-sensitising factor adiponectin is reduced in obese and insulin-resistant subjects.^{91–92} Interestingly, enlarged adipocytes seem to express pro-inflammatory and anti-inflammatory factors with a shift towards dominance of pro-inflammatory adipokines compared with smaller adipocytes.⁹³

Recent data indicate that adipose tissue of obese individuals is infiltrated by macrophages, which may be a major source of locally produced pro-inflammatory adipokines.^{94–95} There seems to be cross-talk between adipocytes and macrophages within adipose tissue. For example, macrophage-secreted factors exert effects on adipocytes that may increase systemic inflammation and insulin resistance associated with obesity.⁹⁶ The mechanisms underlying the impaired adipokine secretion and macrophage infiltration in adipose tissue in obesity remain to be elucidated, but there is evidence to support a major role for adipose tissue hypoxia in these events.

Adipose tissue hypoxia in obesity

Evidence has recently emerged that adipose tissue hypoxia is present in obese mice.⁹⁷ Accordingly, it has been shown that weight loss decreases adipose tissue expression of hypoxia-responsive genes.⁹⁸ An alteration in oxygen pressure and/or oxygen content of the blood was not apparent in the obese animals.⁹⁷ Based on the above, it can be speculated that hypoxia in adipose tissue may contribute to obesity-related insulin resistance.

Since adipose tissue blood flow per unit tissue mass is reduced in obese humans^{99–100} and rodents,⁹⁷ decreased blood supply to adipose tissue may explain adipose tissue hypoxia in obesity. Indeed, it has been suggested that the expansion of adipose tissue mass during the progressive development of obesity may lead to hypoxia in certain parts of adipose tissue because angiogenesis is insufficient to maintain normoxia in the entire adipose tissue depot.¹⁰¹ As a consequence, adipose tissue hypoxia may induce increased secretion of inflammatory factors, acute phase proteins and angiogenic factors by adipose tissue in order to increase blood flow and vascularisation. The transcription factor hypoxia inducible factor-1 (HIF-1) is a key regulator in the response to alterations in oxygen tension and modulates the expression of genes that are involved in angiogenesis, erythropoiesis, inflammation and glucose metabolism.^{102–103}

Recent studies have shown that adiponectin and PPAR γ mRNA expression were decreased, whereas PAI-1 and visfatin mRNA expression were increased in hypoxic 3T3-L1 adipocytes compared with normoxic control cells.^{97–104–105} Likewise, hypoxia altered the expression and secretion of inflammation-related adipokines in human adipocytes.¹⁰⁶ Furthermore, weight loss led to improved oxygenation and reduced inflammation in dietary obese mice.¹⁰⁷ Second, severe hypoxia may induce adipocyte death. A hypoxic environment devoid of nutrients prevents the cell undergoing energy-dependent apoptosis and cells become necrotic.¹⁰⁸ Subsequently, macrophages fuse and form syncytia that sequester and scavenge adipocyte debris.¹⁰⁹ Hypoxia-induced adipocyte death may thus evoke macrophage infiltration in the adipose tissue of obese individuals. These data suggest that adipose tissue hypoxia modulates—either directly or indirectly via recruitment of macrophages—adipokine expression and secretion and may therefore provide an important link between obesity and insulin resistance.⁷¹ Third, hypoxia inhibits adipocyte differentiation¹¹⁰ which appears to be a precipitating factor in the development of type 2 diabetes, as mentioned earlier.¹¹¹ Finally, unfolded protein response, an HIF-1-independent signalling pathway, contributes to cellular adaptation to hypoxia.¹¹² Many disturbances including hypoxia cause accumulation of unfolded proteins in the endoplasmic reticulum (ER)^{112–113} leading to ER stress.¹¹⁴ It has been shown that ER stress is increased in the adipose tissue and liver of obese mice, which activates the inflammatory response, thereby contributing to insulin resistance.¹¹⁵ In conclusion, adipose tissue hypoxia—possibly due to impaired adipose tissue blood flow as a consequence of adipose tissue expansion—may be an important factor in the development of obesity-related insulin resistance via effects on adipokine expression and/or adipocyte differentiation.⁷¹

In summary, evidence suggests that enlargement of adipocytes, impaired adipose tissue blood flow, adipose tissue hypoxia, local inflammation and macrophage infiltration in adipose tissue are interrelated in obesity and may lead to disturbances in adipokine secretion and excessive fat storage in non-adipose tissues, which together may result in insulin resistance and ultimately type 2 diabetes mellitus.⁷¹

POTENTIAL IMPACT OF ADIPOSE TISSUE DYSFUNCTION ON THE PATHOPHYSIOLOGY OF COPD

Adipose tissue and fat oxidative capacity in COPD

There is a lack of studies on adipose tissue morphology in patients with COPD. While available evidence suggests an increased prevalence of abdominal obesity at the macroscopic level,¹⁴ no microscopic data are available in COPD. As a consequence, possible alterations in size, differentiation and lipid buffering capacity of adipocytes remain unknown.

If fatty acid delivery to skeletal muscle exceeds fat oxidation, lipids and lipid intermediates accumulate in skeletal muscle cells. Intramyocellular fat accumulation is closely related to the development of insulin resistance.¹¹⁶ Reduced peripheral skeletal muscle fat oxidative capacity is consistently reported in patients with COPD.¹¹⁷ It is reflected by a muscle fibre type shift from type I to II (or slow-twitch to fast-twitch) and reduced activities of enzymes involved in oxidative energy metabolism.¹¹⁸ In the case of high non-esterified fatty acid (FFA) release into the circulation in COPD, the reduced fat oxidative capacity would be a potential risk factor for development of metabolic syndrome. Since obesity is associated with increased exposure of skeletal muscle to triacylglycerol and FFA, obese patients with COPD would be at particular risk. Indeed, increased fasting lipolytic rate and enhanced levels of circulatory FFA have been reported in hypoxaemic patients with COPD in comparison with controls,¹¹⁹ although another study did not confirm this.¹²⁰ Also, reduced intramyocellular triglyceride content was reported in a small group of normal weight patients with COPD. However, levels of oxidative enzymes were not reported in that study and no obese patients with COPD were included.

Adipose tissue as a source of inflammation in COPD

In addition to pulmonary inflammation, persistent low-grade systemic inflammation is frequently demonstrated in patients with COPD. Increased levels of pro-inflammatory cells and mediators have been reported in the circulation of patients with COPD. Enhanced plasma concentrations of fibrinogen, C-reactive protein (CRP), TNF α and circulating leucocytes have been consistently observed in patients with stable COPD compared with healthy controls,¹²¹ while raised levels of IL6,⁶⁸ IL8,¹²² IL10⁶⁸ and IL18¹²³ have also been shown. The presence of low-grade systemic inflammation was associated with several systemic consequences in patients with COPD, including reduced exercise capacity and worse health-related quality of life.¹²⁴ Also, increased circulatory levels of TNF α , IL6 and their soluble receptors were observed in FFM-depleted patients with COPD in comparison with patients with preserved FFM, both in patients with low body weight and in those with normal BMI.¹²⁵ This suggests a role for systemic inflammation in COPD-related muscle wasting, even in patients without apparent weight loss such as subgroups of sarcopenic or obese patients. In addition, a link between systemic inflammation and markedly increased cardiovascular mortality in COPD was suggested.⁶³

Despite the growing awareness that systemic inflammation is a hallmark in the pathogenesis of COPD, remarkably little is known about the underlying mechanisms. Although it is often hypothesised that inflammation in the systemic compartment is the result of spill-over of the inflammatory process in the airways, lung parenchyma and pulmonary vasculature, evidence from cross-sectional studies indicates no correlation between pulmonary and circulatory inflammatory markers in stable COPD.¹²²

Figure 2 Proposed mechanistic links between chronic obstructive pulmonary disease, body composition, adipose tissue dysfunction, systemic inflammation and insulin resistance.

Adipose tissue is another possible source of systemic inflammation. As discussed above, adipose tissue expresses several pro-inflammatory mediators with potential systemic metabolic effects. The importance of these adipokines released from fat tissue in the pathogenesis of systemic inflammation in obesity is recognised. By measurements of arteriovenous concentration differences of cytokines in combination with measurement of adipose tissue blood flow, release of IL6 from abdominal subcutaneous adipose tissue into the systemic circulation has been demonstrated in healthy human subjects.⁸⁸ Furthermore, the rate of IL6 release per unit abdominal subcutaneous adipose tissue has been shown to be equal or greater in obese subjects, depending on the degree of obesity.¹²⁶ Taking into consideration the absolute increased fat mass in the obese, these findings indicate that IL6 release from abdominal subcutaneous adipose tissue is raised at the whole-body level in these individuals. In another study in obese subjects, IL6 concentrations in the portal vein, which drains the visceral fat, were significantly increased compared with IL6 levels in peripheral arterial blood, demonstrating that visceral fat is an important source of IL6 in obesity.¹²⁷ Furthermore, portal vein IL6 levels were related to arterial C-reactive protein concentrations, suggesting a mechanistic link between visceral fat mass and systemic inflammation in vivo.

The role of adipose tissue in the pathogenesis of systemic inflammation in patients with COPD has not been studied. Also, the possible cross-talk between fat mass-derived inflammatory factors and loss of FFM in COPD is speculative. However, based on the foregoing, it can be hypothesised that, in patients with early stage COPD with obesity or relatively abundant fat mass, adipose tissue may act as an additional source of inflammation (fig 2). Since systemic inflammation is associated with loss of skeletal muscle in COPD,¹²⁵ this may contribute to loss of FFM and amplify alterations in body composition towards loss of lean body mass and preservation of fat mass. Additionally, excretion of adipokines by adipose tissue in COPD might be reinforced by the presence of chronic or intermittent hypoxia.

Adipose tissue hypoxia and insulin resistance in COPD

As mentioned earlier, there is evidence for adipose tissue hypoxia in obesity.⁹⁷ It has recently been shown that hypoxia induces expression and secretion of several pro-inflammatory mediators including IL6, leptin, PAI-1 and monocyte migration

inhibitory factor (MIF) in human adipocytes.¹⁰⁶ As stated above, adipose tissue hypoxia might thus provide an important link between obesity and insulin resistance through secretion of inflammatory adipokines.

In patients with COPD with obesity or relatively abundant fat mass, the link between adipose tissue hypoxia and systemic metabolic effects might be further enhanced by the presence of systemic hypoxaemia in more advanced stages of disease, which does not occur in healthy obese individuals. Although no studies have directly focused on this issue, there is growing evidence for insulin resistance in COPD, especially in normal to overweight and hypoxic patients. Glucose intolerance was first reported in normal weight patients with chronic hypoxaemic COPD on long-term oxygen therapy, although the results might have been confounded by the use of systemic glucocorticosteroids.¹²⁸ More recently, the presence of insulin resistance was reported in normal weight patients with COPD with normal systemic oxygen saturation.⁶⁷ Interestingly, both BMI and the systemic IL6 concentration were independent determinants of insulin resistance. In line with this observation, there is evidence for decreased insulin sensitivity in a large group of normal weight patients with COPD in comparison with underweight patients and normal weight controls.⁶⁸ However, insulin sensitivity was not related to BMI in that study. Finally, supplemental oxygen resulted in increased glucose tolerance and insulin sensitivity in hypoxaemic patients with COPD, and this effect tended to be greater in obese than in lean subjects.⁶⁹

Potential mechanistic links between adipose tissue mass, local and systemic hypoxia, systemic inflammation and insulin resistance in patients with COPD offer challenging research opportunities, not only in the extrapulmonary manifestations of the disease but also in the area of pathogenesis of obesity-related metabolic disturbances. Future studies need to reveal the potential effects of excessive fat mass on pathophysiology and prognosis in COPD and possible implications for pharmacological management, dietary interventions and pulmonary rehabilitation.

Competing interests: None.

REFERENCES

1. Rabe KF, Hurd S, Anzueto A, *et al*. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;**176**:532–55.

2. **World Health Organization.** Overweight and obesity: a new nutrition emergency? Monitoring the rapidly emerging public health problem of overweight and obesity: the WHO global database on body mass index. *SCN News* 2004;5–12.
3. **Buist AS, McBurnie MA, Vollmer WM, et al.** International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;**370**:741–50.
4. **Murray CJ, Lopez AD.** Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet* 1997;**349**:1498–504.
5. **World Health Organization.** *Obesity: preventing and managing the global epidemic. Report of a WHO Consultation.* WHO Technical Report Series 894. Geneva: World Health Organization, 2000.
6. **Jubber AS.** Respiratory complications of obesity. *Int J Clin Pract* 2004;**58**:573–80.
7. **Shore SA, Fredberg JJ.** Obesity, smooth muscle, and airway hyperresponsiveness. *J Allergy Clin Immunol* 2005;**115**:925–7.
8. **Poulain M, Doucet M, Major GC, et al.** The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. *CMAJ* 2006;**174**:1293–9.
9. **Pitta F, Troosters T, Spruit MA, et al.** Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**171**:972–7.
10. **Dallman MF, la Fleur SE, Pecoraro NC, et al.** Minireview: glucocorticoids—food intake, abdominal obesity, and wealthy nations in 2004. *Endocrinology* 2004;**145**:2633–8.
11. **Steuten LM, Creutzberg EC, Vrijhoef HJ, et al.** COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. *Prim Care Respir J* 2006;**15**:84–91.
12. **Schokker DF, Visscher TL, Noyens AC, et al.** Prevalence of overweight and obesity in the Netherlands. *Obes Rev* 2007;**8**:101–8.
13. **Eisner MD, Blanc PD, Sidney S, et al.** Body composition and functional limitation in COPD. *Respir Res* 2007;**8**:7.
14. **Marquis K, Maltais F, Duguay V, et al.** The metabolic syndrome in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil* 2005;**25**:226–34.
15. **Filley GF, Beckwith HJ, Reeves JT, et al.** Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. *Am J Med* 1968;**44**:26–38.
16. **Guerra S, Sherrill DL, Bobadilla A, et al.** The relation of body mass index to asthma, chronic bronchitis, and emphysema. *Chest* 2002;**122**:1256–63.
17. **Schols AM, Soeters PB, Dingemans AM, et al.** Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *Am Rev Respir Dis* 1993;**147**:1151–6.
18. **Vestbo J, Prescott E, Almdal T, et al.** Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. *Am J Respir Crit Care Med* 2006;**173**:79–83.
19. **Engelen MP, Schols AM, Lamers RJ, et al.** Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. *Clin Nutr* 1999;**18**:275–80.
20. **Roubenoff R.** The pathophysiology of wasting in the elderly. *J Nutr* 1999;**129**:256–9S.
21. **Collins LC, Hobery PD, Walker JF, et al.** The effect of body fat distribution on pulmonary function tests. *Chest* 1995;**107**:1298–302.
22. **Lazarus R, Sparrow D, Weiss ST.** Effects of obesity and fat distribution on ventilatory function: the normative aging study. *Chest* 1997;**111**:891–8.
23. **Naimark A, Cherniack RM.** Compliance of the respiratory system and its components in health and obesity. *J Appl Physiol* 1960;**15**:377–82.
24. **Sharp JT, Henry JP, Sweany SK, et al.** The total work of breathing in normal and obese men. *J Clin Invest* 1964;**43**:728–39.
25. **Suratt PM, Wilhoit SC, Hsiao HS, et al.** Compliance of chest wall in obese subjects. *J Appl Physiol* 1984;**57**:403–7.
26. **Ray CS, Sue DY, Bray G, et al.** Effects of obesity on respiratory function. *Am Rev Respir Dis* 1983;**128**:501–6.
27. **Ofir D, Laveneziana P, Webb KA, et al.** Ventilatory and perceptual responses to cycle exercise in obese women. *J Appl Physiol* 2007;**102**:2217–26.
28. **Ferretti A, Giampiccolo P, Cavalli A, et al.** Expiratory flow limitation and orthopnea in massively obese subjects. *Chest* 2001;**119**:1401–8.
29. **Rubinstein I, Zamel N, DuBarry L, et al.** Airflow limitation in morbidly obese, nonsmoking men. *Ann Intern Med* 1990;**112**:828–32.
30. **Zerah F, Harf A, Perlemuter L, et al.** Effects of obesity on respiratory resistance. *Chest* 1993;**103**:1470–6.
31. **Thomas PS, Cowen ER, Hulands G, et al.** Respiratory function in the morbidly obese before and after weight loss. *Thorax* 1989;**44**:382–6.
32. **Holley HS, Milic-Emili J, Becklake MR, et al.** Regional distribution of pulmonary ventilation and perfusion in obesity. *J Clin Invest* 1967;**46**:475–81.
33. **Sampson MG, Grassino K.** Neuromechanical properties in obese patients during carbon dioxide rebreathing. *Am J Med* 1983;**75**:81–90.
34. **Gilbert R, Sipple JH, Auchincloss JH Jr.** Respiratory control and work of breathing in obese subjects. *J Appl Physiol* 1961;**16**:21–6.
35. **Kelly TM, Jensen RL, Elliott CG, et al.** Maximum respiratory pressures in morbidly obese subjects. *Respiration* 1988;**54**:73–7.
36. **Dempsey JA, Reddan W, Balke B, et al.** Work capacity determinants and physiologic cost of weight-supported work in obesity. *J Appl Physiol* 1966;**21**:1815–20.
37. **Whipp BJ, Davis JA.** The ventilatory stress of exercise in obesity. *Am Rev Respir Dis* 1984;**129**:S90–2.
38. **Babb TG, Buskirk ER, Hodgson JL.** Exercise end-expiratory lung volumes in lean and moderately obese women. *Int J Obes* 1989;**13**:11–9.
39. **Babb TG, Korzick D, Meador M, et al.** Ventilatory response of moderately obese women to submaximal exercise. *Int J Obes* 1991;**15**:59–65.
40. **Chilif M, Keochkerian D, Feki Y, et al.** Inspiratory muscle activity during incremental exercise in obese men. *Int J Obes (Lond)* 2007;**31**:1456–63.
41. **Li J, Li S, Feuers RJ, et al.** Influence of body fat distribution on oxygen uptake and pulmonary performance in morbidly obese females during exercise. *Respirology* 2001;**6**:9–13.
42. **Kress JP, Pohlman AS, Alverdy J, et al.** The impact of morbid obesity on oxygen cost of breathing (VO₂(RESP)) at rest. *Am J Respir Crit Care Med* 1999;**160**:883–6.
43. **Lenmarken C, Sandstedt S, von Schenck H, et al.** Skeletal muscle function and metabolism in obese women. *JPEN J Parenter Enteral Nutr* 1986;**10**:583–7.
44. **Alpert MA, Lambert CR, Terry BE, et al.** Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. *Int J Obes Relat Metab Disord* 1995;**19**:550–7.
45. **Swinburn CR, Cooper BG, Mould H, et al.** Adverse effect of additional weight on exercise against gravity in patients with chronic obstructive airways disease. *Thorax* 1989;**44**:716–20.
46. **Gibson GJ.** Obesity, respiratory function and breathlessness. *Thorax* 2000;**55**(Suppl 1):S41–4.
47. **O'Donnell DE, Ofir D, Laveneziana P.** Patterns of cardiopulmonary response to exercise in lung diseases. *Eur Respir Monogr* 2006;**40**:69–92.
48. **O'Donnell DE, Voduc N.** *Mechanisms of dyspnea in restrictive lung disorders.* 2nd ed. Boca Raton, FL: Taylor & Francis Group, 2005:87–114.
49. **O'Donnell DE, Hamilton AL, Webb KA.** Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. *J Appl Physiol* 2006;**101**:1025–35.
50. **Engelen MP, Schols AM, Does JD, et al.** Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. *Am J Clin Nutr* 2000;**71**:733–8.
51. **Baarends EM, Schols AM, Mostert R, et al.** Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. *Eur Respir J* 1997;**10**:2807–13.
52. **Visser M, Langlois J, Guralnik JM, et al.** High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. *Am J Clin Nutr* 1998;**68**:584–90.
53. **Sternfeld B, Ngo L, Satariano WA, et al.** Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. *Am J Epidemiol* 2002;**156**:110–21.
54. **Schols AM, Broekhuizen R, Welting-Scheepers CA, et al.** Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr* 2005;**82**:53–9.
55. **Landbo C, Prescott E, Lange P, et al.** Prognostic value of nutritional status in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**160**:1856–61.
56. **Wilson DO, Rogers RM, Wright EC, et al.** Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. *Am Rev Respir Dis* 1989;**139**:1435–8.
57. **Chailleux E, Laaban JP, Veale D.** Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. *Chest* 2003;**123**:1460–6.
58. **Peeters A, Barendregt JJ, Willekens F, et al.** Obesity in adulthood and its consequences for life expectancy: a life-table analysis. *Ann Intern Med* 2003;**138**:24–32.
59. **Kalantar-Zadeh K, Horwich TB, Oreopoulos A, et al.** Risk factor paradox in wasting diseases. *Curr Opin Clin Nutr Metab Care* 2007;**10**:433–42.
60. **Watson L, Vonk JM, Lofdahl CG, et al.** Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. *Respir Med* 2006;**100**:746–53.
61. **Schunemann HJ, Dorn J, Grant BJ, et al.** Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. *Chest* 2000;**118**:656–64.
62. **Hole DJ, Watt GC, Davey-Smith G, et al.** Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ* 1996;**313**:711–6.
63. **Sin DD, Man SF.** Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. *Circulation* 2003;**107**:1514–9.
64. **Fabbri LM, Rabe KF.** From COPD to chronic systemic inflammatory syndrome? *Lancet* 2007;**370**:797–9.
65. **Eckel RH, Grundy SM, Zimmet PZ.** The metabolic syndrome. *Lancet* 2005;**365**:1415–28.
66. **Gami AS, Witt BJ, Howard DE, et al.** Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007;**49**:403–14.
67. **Bolton CE, Evans M, Ionescu AA, et al.** Insulin resistance and inflammation: a further systemic complication of COPD. *COPD* 2007;**4**:121–6.
68. **Koehler F, Doehner W, Hoernig S, et al.** Anorexia in chronic obstructive pulmonary disease: association to cachexia and hormonal derangement. *Int J Cardiol* 2007;**119**:83–9.
69. **Jakobsson P, Jorfeldt L.** Oxygen supplementation increases glucose tolerance during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with severe COPD and chronic hypoxaemia. *Clin Physiol Funct Imaging* 2006;**26**:271–4.
70. **Grundey SM, Brewer HB Jr, Cleeman JI, et al.** Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004;**109**:433–8.

71. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. *Physiol Behav* 2008;**94**:206–18.
72. Frayn KN. Adipose tissue and the insulin resistance syndrome. *Proc Nutr Soc* 2001;**60**:375–80.
73. Forouhi NG, Jenkinson G, Thomas EL, et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. *Diabetologia* 1999;**42**:932–5.
74. Koyama K, Chen G, Lee Y, et al. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. *Am J Physiol* 1997;**273**:E708–13.
75. Bjorntorp P. Liver triglycerides and metabolism. *Int J Obes Relat Metab Disord* 1995;**19**:839–40.
76. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 2004;**89**:2548–56.
77. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw* 2006;**17**:4–12.
78. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. *Int J Obes Relat Metab Disord* 2003;**27**(Suppl 3):S25–8.
79. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med* 2005;**11**:183–90.
80. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. *Nat Med* 2001;**7**:1138–43.
81. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. *Nature* 1997;**389**:610–4.
82. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. *J Clin Endocrinol Metab* 2000;**85**:3338–42.
83. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. *Am J Physiol Endocrinol Metab* 2003;**285**:E527–33.
84. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. *J Clin Invest* 1995;**95**:2409–15.
85. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. *Circulation* 2003;**107**:671–4.
86. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 2001;**280**:E745–51.
87. Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF-alpha, leptin and IL6 levels in obese women. *Int J Obes Relat Metab Disord* 2004;**28**:993–7.
88. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. *J Clin Endocrinol Metab* 1997;**82**:4196–200.
89. Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. *Diabetes* 2000;**49**:1374–80.
90. Klein S, Coppack SW, Mohamed-Ali V, et al. Adipose tissue leptin production and plasma leptin kinetics in humans. *Diabetes* 1996;**45**:984–7.
91. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 2000;**20**:1595–9.
92. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab* 2001;**86**:1930–5.
93. Skurk T, Alberti-Huber C, Herder C, et al. Relationship between adipocyte size and adipokine expression and secretion. *J Clin Endocrinol Metab* 2007;**92**:1023–33.
94. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* 2003;**112**:1796–808.
95. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003;**112**:1821–30.
96. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. *Biochem Biophys Res Commun* 2006;**341**:507–14.
97. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. *Diabetes* 2007;**56**:901–11.
98. Cencello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* 2005;**54**:2277–86.
99. Blaak EE, van Baak MA, Kemerink GJ, et al. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. *Metabolism* 1995;**44**:183–7.
100. Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. *Clin Sci (Lond)* 1996;**91**:679–83.
101. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. *Br J Nutr* 2004;**92**:347–55.
102. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. *J Clin Invest* 2000;**106**:809–12.
103. Wenger RH. Cellular adaptation to hypoxia: O₂-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O₂-regulated gene expression. *Faseb J* 2002;**16**:1151–62.
104. Chen B, Lam KS, Wang Y, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. *Biochem Biophys Res Commun* 2006;**341**:549–56.
105. Segawa K, Fukuhara A, Hosogai N, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. *Biochem Biophys Res Commun* 2006;**349**:875–82.
106. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. *Pflugers Arch* 2007;**455**:479–92.
107. Ye J, Gao Z, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. *Am J Physiol Endocrinol Metab* 2007;**293**:E1118–28.
108. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. *J Clin Pathol* 2004;**57**:1009–14.
109. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J Lipid Res* 2005;**46**:2347–55.
110. Yun Z, Maecker HL, Johnson RS, et al. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Strat13: a mechanism for regulation of adipogenesis by hypoxia. *Dev Cell* 2002;**2**:331–41.
111. Weyer C, Foley JE, Bogardus C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. *Diabetologia* 2000;**43**:1498–506.
112. Bi M, Naczki C, Koritzinsky M, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. *EMBO J* 2005;**24**:3470–81.
113. Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. *Mol Cancer Res* 2005;**3**:597–605.
114. Carriere A, Carmona MC, Fernandez Y, et al. Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect. *J Biol Chem* 2004;**279**:40462–9.
115. Nakatani Y, Kaneto H, Kawamori D, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. *J Biol Chem* 2005;**280**:847–51.
116. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. *Diabetes* 1999;**48**:1113–9.
117. Gosker H, Zeegers M, Wouters E, et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. *Thorax* 2007;**62**:944–9.
118. American Thoracic Society/European Respiratory Society Statement. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**159**:S1–40.
119. Jakobsson P, Jorfeldt L, von Schenck H. Fat metabolism and its response to infusion of insulin and glucose in patients with advanced chronic obstructive pulmonary disease. *Clin Physiol* 1995;**15**:319–29.
120. Schiffelers SL, Blaak EE, Baarends EM, et al. beta-Adrenoceptor-mediated thermogenesis and lipolysis in patients with chronic obstructive pulmonary disease. *Am J Physiol Endocrinol Metab* 2001;**280**:E357–64.
121. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax* 2004;**59**:574–80.
122. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. *Am J Respir Crit Care Med* 2002;**166**:1218–24.
123. Petersen AM, Penkowa M, Iversen M, et al. Elevated levels of IL18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. *Lung* 2007;**185**:161–71.
124. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. *Thorax* 2006;**61**:17–22.
125. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**164**:1414–8.
126. Goossens GH, Jocken JWE, van Baak MA, et al. Short-term beta-adrenergic regulation of leptin, adiponectin and IL6 secretion in vivo in lean and obese subjects. *Diabetes Obes Metab* 22 Apr 2008 [Epub ahead of print].
127. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. *Diabetes* 2007;**56**:1010–3.
128. Hjalmarsen A, Aasebo U, Birkeland K, et al. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. *Diabetes Metab* 1996;**22**:37–42.